Difference between revisions of "Estrogen receptor"
Jump to navigation
Jump to search
Jensflorian (talk | contribs) (→Positive: +Prolactioma) |
|||
| (3 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
{{ Infobox immunostain | |||
| Name = {{PAGENAME}} | |||
| Image = Stomach Metastatic Breast Carcinoma, IHC for Estrogen Receptor (5610737866).jpg | |||
| Width = | |||
| Caption = ER+ve in metastatic breast carcinoma. | |||
| Abbrev = ER | |||
| Synonyms = | |||
| Similar = | |||
| Clones = | |||
| Use = | |||
| Subspecial = | |||
| Pattern = nuclear staining | |||
| Positive = Breast and endometrial carcinoma | |||
| Negative = | |||
| Other = | |||
}} | |||
'''Estrogen receptor''', abbreviated '''ER''', is a common [[immunostain]]. | '''Estrogen receptor''', abbreviated '''ER''', is a common [[immunostain]]. | ||
| Line 24: | Line 41: | ||
==See also== | ==See also== | ||
*[[Breast pathology]]. | *[[Breast pathology]]. | ||
*[[Tamoxifen]]. | |||
==References== | ==References== | ||
Latest revision as of 18:27, 30 August 2023
| Estrogen receptor | |
|---|---|
| Immunostain in short | |
.jpg) ER+ve in metastatic breast carcinoma. | |
| Abbreviation | ER |
| Normal staining pattern | nuclear staining |
| Positive | Breast and endometrial carcinoma |
Estrogen receptor, abbreviated ER, is a common immunostain.
General
- Nuclear stain - like most other "p" stains.
- In the context of breast pathology it is a class II IHC test, as it is used for treatment decisions by itself.[1]
Positive
- Normal breast - usually patchy staining.
- Florid epithelial hyperplasia of the usual type - usually patchy staining[2] - see immunostains for typing and diagnosis of breast lesions.
- Breast carcinoma - most.
- Ductal carcinoma in situ - most, usually diffuse[2] - see immunostains for typing and diagnosis of breast lesions.
- Invasive lobular carcinoma - all.
- Invasive ductal carcinoma of the breast - most.
- Endometrial carcinomas.
- PRL-producing pituitary adenomas (Prolactioma)[3]
Occasionally positive
- Lung adenocarcinoma - dependent on the ER subunit target - ERα ~1%, ERβ ~79%.[4]
Negative
See also
References
- ↑ Torlakovic, EE.; Riddell, R.; Banerjee, D.; El-Zimaity, H.; Pilavdzic, D.; Dawe, P.; Magliocco, A.; Barnes, P. et al. (Mar 2010). "Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests.". Am J Clin Pathol 133 (3): 354-65. doi:10.1309/AJCPDYZ1XMF4HJWK. PMID 20154273.
- ↑ 2.0 2.1 O'Malley, Frances P.; Pinder, Sarah E. (2006). Breast Pathology: A Volume in Foundations in Diagnostic Pathology series (1st ed.). Churchill Livingstone. pp. 276. ISBN 978-0443066801.
- ↑ Delgrange, E.; Vasiljevic, A.; Wierinckx, A.; François, P.; Jouanneau, E.; Raverot, G.; Trouillas, J. (Jun 2015). "Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth.". Eur J Endocrinol 172 (6): 791-801. doi:10.1530/EJE-14-0990. PMID 25792376.
- ↑ Tanaka, K.; Shimizu, K.; Kakegawa, S.; Ohtaki, Y.; Nagashima, T.; Kaira, K.; Horiguchi, J.; Oyama, T. et al. (2016). "Prognostic significance of aromatase and estrogen receptor beta expression in EGFR wild-type lung adenocarcinoma.". Am J Transl Res 8 (1): 81-97. PMID 27069542.
- ↑ Hu, WW.; Tao, JH.; Li, GM.; Xu, X.; Yang, XM. (Mar 2010). "[Value of ER, VIM, CEA and p16 detection in the diagnosis and differential diagnosis of primary endocervical and endometrial adenocarcinomas].". Nan Fang Yi Ke Da Xue Xue Bao 30 (3): 526-8, 531. PMID 20335127.